Single Drug Polyestradiol Phosphate Therapy in Pro static Cancer

@article{Stege1988SingleDP,
  title={Single Drug Polyestradiol Phosphate Therapy in Pro static Cancer},
  author={Reinhard Stege and Kjell Carlstr{\"o}m and Lars G. Collste and Ambj{\"o}rn Eriksson and Peter Henriksson and {\AA}ke Pousette},
  journal={American Journal of Clinical Oncology},
  year={1988},
  volume={11},
  pages={S101–103}
}
Serum concentrations of testosterone (T) and estradiol-17β (E2) were analyzed in prostatic cancer patients treated with 160, 240, or 320 mg polyestradiol phosphate (PEP) i.m. every fourth week as single drug therapy during a 6 month period. Estrogen effects on the liver were studied by analyzing serum levels of sex hormone binding globulin (SHBG) in the 320 mg group and compared with values obtained in patients treated with 80 mg PEP i.m. every fourth week + oral ethinylestradiol (EE2) 150 μg… 
Single‐drug parenteral estrogen treatment in prostatic cancer: A study of two maintenance‐dose regimens
Treatment of 17 patients with prostatic cancer with 320 mg polyestradiol phosphate (PEP) as intramuscular injections every fourth week suppressed serum testosterone (T) values to orchidectomy levels
Hormonal regulation of serum lipoprotein (a) levels: effects of parenteral administration of estrogen or testosterone in males.
TLDR
During parenteral administration of estrogens or androgens, diverging effects on Lp(a) and serum lipoproteins were observed, suggesting that the regulatory role of sex hormones on serum Lp (a) levels may depend on their capability to influence hepatic metabolic pathways of L p(a).
A comparison of androgen status in patients with prostatic cancer treated with oral and/or parenteral estrogens or by orchidectomy
TLDR
Both estrogen treatment regimens were as effective as orchidectomy in reducing circulating levels of T and A‐4 and the more pronounced effects of oral estrogens on circulating adrenal androgens may reflect an altered liver metabolism associated with this route of administration.
IMMEDIATE ESTROGEN OR ESTRAMUSTINE PHOSPHATE THERAPY VERSUS DEFERRED ENDOCRINE TREATMENT IN NONMETASTATIC PROSTATE CANCER: A RANDOMIZED MULTICENTER STUDY WITH 15 YEARS OF FOLLOWUP ROLF LUNDGREN, OMAN NORDLE, KENNETH JOSEFSSON AND THE SOUTH SWEDEN PROSTATE CANCER STUDY GROUP*
TLDR
Patients with moderately well differentiated cancer (stage greater than TOa) who received early treatment with estramustine phosphate had the lowest risk of metastases or death from prostatic cancer, while those with well differentiated cancers did best on early polyestradio phosphate plus ethinylestradiol treatment.
Therapy Insight: parenteral estrogen treatment for prostate cancer—a new dawn for an old therapy
TLDR
Parenteral estrogen therapy has the advantage of giving protection against the effects of andropause, which are induced by conventional androgen suppression and include osteoporotic fracture, hot flashes, asthenia and cognitive dysfunction.
Parenteral polyoestradiol phosphate vs orchidectomy in the treatment of advanced prostatic cancer. Efficacy and cardiovascular complications: a 2-year follow-up report of a national, prospective prostatic cancer study. Finnprostate Group.
TLDR
Parenteral PEP (240 mg/month) seems to be as efficient as orchidectomy in inhibiting disease in patients with advanced prostatic cancer, and the difference was statistically significant during the first year of treatment.
...
1
2
3
...